賀智敏，男，醫(yī)學(xué)博士，廣州醫(yī)學(xué)院教授，博士生導(dǎo)師；現(xiàn)任廣州醫(yī)學(xué)院腫瘤研究所所長兼附屬腫瘤醫(yī)院中心實(shí)驗(yàn)室主任。1982年畢業(yè)于湖南醫(yī)學(xué)院醫(yī)療系，先后獲學(xué)士、碩士、博士學(xué)位；1998年2007年間作為訪問學(xué)者先后在香港大學(xué)微生物系jfsoft.net.cn、美國杜克大學(xué)癌癥研究中心及美國科羅拉多大學(xué)醫(yī)學(xué)中心工作4年�，F(xiàn)擔(dān)任湖南省病理生理學(xué)會(huì)副理事長兼秘書長，國際病理科學(xué)與臨床雜志副主編及多家雜志編委；廣州市“腫瘤學(xué)”重點(diǎn)扶持學(xué)科項(xiàng)目負(fù)責(zé)人。
先后主持國家自然基金3項(xiàng)、省部級(jí)科研課題4項(xiàng)，其他項(xiàng)目5余項(xiàng)，在Nature Medicine,Cell stem Cell,Cancer Res, Nucleic Acids Research, Oncogene, Cancer Letter等雜志發(fā)表科研論文110余篇，其中SCI收錄論文40篇。獲得2項(xiàng)省級(jí)成果，培養(yǎng)博士研究生8名，碩士研究生30名,在站博士后1人。
主要研究方向：惡性腫瘤發(fā)病和治療耐受的分子機(jī)制
聯(lián)系方式：E-mail:hezhimin2005@yahoo.com; Tel: 020-83492353
近3年以通訊作者發(fā)表的主要文章：
1. Weijia Zhang，Meilin Feng，Guopei Zheng，Ye Chen，Xuedong Wang，Bo Peng,Jiang Yin, Yanhui Yu, Zhimin He Chemoresistance to 5-fluorouracil induces epithelial- mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem. Biophys. Res. Commun. 2012,417：679-685 (IF-2.595)
2. Guopei Zheng, Yan Xiong,, Sisi Yi,, Weijia Zhang, Bo Peng, Qiong Zhang, Zhimin He14-3-3r regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation FEBS Lett. 2012, 586：163-168 (IF-3.601)
3. Bo Peng, Sisi Yi, Yixue Gu, Guopei Zheng and Zhimin He Purification and biochemical characterization of a novel protein—tongue cancer chemotherapy resistance-associated protein1 (TCRP1) Protein Expression and Purification. 2012，82:360-367 (IF-1.644)
4. Weijia Zhang, Wei Ding, Ye Chen, Meilin Feng, Yongmei Ouyang, Yanhui Yu, Zhimin He. Upregulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF-7 breast cancer cells. Acta Biochim Biophys. Sin. 2011，43:647-53 (IF=1.547)
5. Yixue Gu, Shasha Fan, Yan Xiong, Bo Peng, Guopei Zheng, Yanhui Yu, Yongmei Ouyang,Zhimin He Cloning and functional characterization of TCRP1, a novel gene mediating resistance to jfsoft.net.cn cisplatin in an oral squamous cell carcinoma cell line . FEBS letters. 2011,585:881-887 (IF-3.601)
6. Gu Y, Fan S, Liu B, Zheng G, Yu Y, Ouyang Y, He Z. TCRP1 promotes radioresistance of oral squamous cell carcinoma cells via Akt signal pathway. Mol Cell Biochem. 2011，357：107-113 (IF=2.168)
7. Xuedong Wang, Xingang Wu, Chengkun Wang, Weijia Zhang, Yanhui Yu, Yongmei ouyang, Zhimin He Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through NF-κB pathway in MCF-7 cells FEBS letters. 2010，584：3392-3397 (IF-3.601)
8. Guopei Zheng, Fang Peng, Renkui Ding, Yanhui Yu,Yongmei Ouyang, Zhuchu Chen, Zhiqiang Xiao, Zhimin He. Identification of proteins responsible for the multiple drug resistance in 5-Fluorouracil-induced breast cancer cell using proteomics analysis J. Cancer Res and Clinical Oncology 2010, 136(10):1477-88 (IF=2.485)
9. Guopei Zheng, Min Zhou, Xinrong Ou, Bo Peng, Yanhui Yu, Fangren Kong, Yongmei Ouyang, Zhimin He. Identification of CA Ⅸ as a contributor to pingyangmycin induced drug resistance in human tongue cancer cell. FEBS Journal. 2010，277:4506-4518 (JF=3.129)
10. Cheng-kun Wang, Jian-guo Cao, Bo Peng, Yi-xue Gu, Guo-pei Zheng, Zhi-min He. Inhibition of growth and motility of human A549 lung carcinoma cells by a recombined vascular basement membrane derived peptide. Cancer Letter 2010, 292: 261-268(IF=4.864)
11. Cheng-kun Wang, Jian-guo Cao, Jia-quan Qu, Bo Peng, Yi-xue Gu, Zhi-min He. Recombinant vascular basement membrane derived multifunctional peptide blocks endothelial jfsoft.net.cn cell angiogenesis & Neovascularization J. Cell Biochemisthy 2010, 111(2):453-60.(IF=3.422)
12. X. D.Wang, B. L. Wang, S. L. Ye, Y. Q. Liao, L. F. Wang and Z. M. He. Non-invasive foetal RHD genotyping via real-time PCR of foetal DNA from Chinese RhD-negative maternal plasma. Eur J Clin Invest 2009; 39 (7): 607–617 (IF 2.8 )
13. Janhui Yuan, Hui Lv, Bo Peng, Chengkun Wang, Yanhui Yu, Zhimin He. Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009，63：1103-1110 (IF=2.74)
